Efficacy and safety of tafluprost 0.0015% – retrospective analysis of real-world data from the Philippines
Authors Tumbocon JA, Macasaet AM
Received 25 March 2019
Accepted for publication 29 July 2019
Published 27 August 2019 Volume 2019:13 Pages 1627—1634
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Joseph Anthony Tumbocon,1,2 Anne Marie Macasaet1
1Eye Institute, St. Luke’s Medical Center, Quezon City, Philippines; 2Department of Ophthalmology, St. Luke’s College of Medicine, Quezon City, Philippines
Correspondence: Joseph Anthony Tumbocon
Eye Institute, St. Luke’s Medical Center, 279 E. Rodriguez Sr. Blvd., Quezon City 1102, Philippines
Tel +632 789 7700 Ext 7212
Fax +632 789 7700 Ext 7212
Purpose: To investigate the IOP lowering effect and safety of tafluprost 0.0015% in a routine clinical setting in the Philippines.
Patients and methods: A retrospective review of glaucoma patients receiving tafluprost 0.0015% (BAK 0.001% preserved) with a minimum follow-up of 3 months was conducted. Main outcome measure was the mean IOP change at month 3. Secondary outcome measures included longitudinal IOP assessments and occurrence of any adverse events.
Results: Three-hundred twenty-nine eyes of 177 patients with mean age 64.8 years were included and followed for mean 8.8 months. Most common diagnosis was primary open-angle glaucoma (POAG) (34.9%), followed by primary angle-closure (PAC) glaucoma post-laser iridotomy (24.0%), PAC post-laser iridotomy (15.5%), ocular hypertension (OHT)(14.6%), secondary glaucoma (6.7%), and normal-tension glaucoma (4.3%). Mean IOP change at month 3 was −6.18 mmHg (SD 4.06), a −26.37% reduction (p<0.001) and IOP reduction was sustained throughout the study period (p<0.001). Sub-group analysis of treatment naïve (n=203); add-on (n=53) and replacement therapy (n=73) showed a 3-month mean IOP reduction of −8.34 mmHg (SD 2.57, p<0.001) or –31.24%, −5.08 mmHg (SD 2.86, p<0.001) or –23.68%, and −1.00 mmHg (SD 3.08; p=0.007) or –6.31%, respectively. There was significant IOP reduction from baseline in both POAG/OHT sub-group and the PAC/PACG post-laser iridotomy with ≥90° open-angle sub-group (p<0.001), sustained up to month 12 post-treatment. However, there was no significant difference in the average absolute (mmHg) or proportional IOP change from baseline between the two sub-groups. Conjunctival hyperemia was the most common adverse reaction occurring in 15% of patients.
Conclusion: Tafluprost was a safe and effective IOP-lowering treatment in this routine clinical setting.
Keywords: tafluprost 0.0015%, primary open-angle glaucoma, IOP reduction
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]